Literature DB >> 35939208

Current and Prospective Applications of CRISPR-Cas12a in Pluricellular Organisms.

Shaheen Khan1,2, Erwan Sallard3.   

Abstract

CRISPR-Cas systems play a critical role in the prokaryotic adaptive immunity against mobile genetic elements, such as phages and foreign plasmids. In the last decade, Cas9 has been established as a powerful and versatile gene editing tool. In its wake, the novel RNA-guided endonuclease system CRISPR-Cas12a is transforming biological research due to its unique properties, such as its high specificity or its ability to target T-rich motifs, to induce staggered double-strand breaks and to process RNA arrays. Meanwhile, there is an increasing need for efficient and safe gene activation, repression or editing in pluricellular organisms for crop improvement, gene therapy, research model development, and other goals. In this article, we review CRISPR-Cas12a applications in pluricellular organisms and discuss how the challenges characteristic of these complex models, such as vectorization or temperature variations in ectothermic species, can be overcome.
© 2022. The Author(s).

Entities:  

Keywords:  CRISPR-Cas12a; Cpf1; Gene therapy; Genome editing; Multiplex gene editing; Plant biotechnology

Year:  2022        PMID: 35939208     DOI: 10.1007/s12033-022-00538-5

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.860


  53 in total

1.  Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.

Authors:  Bernd Zetsche; Jonathan S Gootenberg; Omar O Abudayyeh; Ian M Slaymaker; Kira S Makarova; Patrick Essletzbichler; Sara E Volz; Julia Joung; John van der Oost; Aviv Regev; Eugene V Koonin; Feng Zhang
Journal:  Cell       Date:  2015-09-25       Impact factor: 41.582

Review 2.  CRISPR-mediated adaptive immune systems in bacteria and archaea.

Authors:  Rotem Sorek; C Martin Lawrence; Blake Wiedenheft
Journal:  Annu Rev Biochem       Date:  2013-03-11       Impact factor: 23.643

Review 3.  Diversity, classification and evolution of CRISPR-Cas systems.

Authors:  Eugene V Koonin; Kira S Makarova; Feng Zhang
Journal:  Curr Opin Microbiol       Date:  2017-06-09       Impact factor: 7.934

4.  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Authors:  Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2012-06-28       Impact factor: 47.728

Review 5.  The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit.

Authors:  Karthik Murugan; Kesavan Babu; Ramya Sundaresan; Rakhi Rajan; Dipali G Sashital
Journal:  Mol Cell       Date:  2017-10-05       Impact factor: 17.970

6.  Genome editing in plants with MAD7 nuclease.

Authors:  Qiupeng Lin; Zixu Zhu; Guanwen Liu; Chao Sun; Dexing Lin; Chenxiao Xue; Shengnan Li; Dandan Zhang; Caixia Gao; Yanpeng Wang; Jin-Long Qiu
Journal:  J Genet Genomics       Date:  2021-05-03       Impact factor: 4.275

Review 7.  Cas9, Cpf1 and C2c1/2/3-What's next?

Authors:  Shota Nakade; Takashi Yamamoto; Tetsushi Sakuma
Journal:  Bioengineered       Date:  2017-01-31       Impact factor: 3.269

Review 8.  Delivering CRISPR: a review of the challenges and approaches.

Authors:  Christopher A Lino; Jason C Harper; James P Carney; Jerilyn A Timlin
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 9.  Comparative genomics of defense systems in archaea and bacteria.

Authors:  Kira S Makarova; Yuri I Wolf; Eugene V Koonin
Journal:  Nucleic Acids Res       Date:  2013-03-06       Impact factor: 16.971

Review 10.  Patterns of CRISPR/Cas9 activity in plants, animals and microbes.

Authors:  Luisa Bortesi; Changfu Zhu; Julia Zischewski; Lucia Perez; Ludovic Bassié; Riad Nadi; Giobbe Forni; Sarah Boyd Lade; Erika Soto; Xin Jin; Vicente Medina; Gemma Villorbina; Pilar Muñoz; Gemma Farré; Rainer Fischer; Richard M Twyman; Teresa Capell; Paul Christou; Stefan Schillberg
Journal:  Plant Biotechnol J       Date:  2016-10-11       Impact factor: 9.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.